Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Molecular Partners AG's Enterprise Value is CHF46.11 Mil.
Molecular Partners AG's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was CHF-48.42 Mil. Therefore, Molecular Partners AG's EV-to-OCF for today is -0.95.
The historical rank and industry rank for Molecular Partners AG's EV-to-OCF or its related term are showing as below:
XSWX:MOLN'
s EV-to-OCF Range Over the Past 10 Years
Min: -24.63 Med: -0.21 Max: 3.47
Current: -0.95
During the past 13 years, the highest EV-to-OCF of Molecular Partners AG was 3.47. The lowest was -24.63. And the median was -0.21.
XSWX:MOLN's EV-to-OCF is ranked worse than 64.18% of 1407
companies
in the Biotechnology industry
Industry Median: -3.45
vs XSWX:MOLN: -0.95
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Molecular Partners AG (XSWX:MOLN) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Molecular Partners AG's PE Ratio (TTM) for today is calculated as:
Molecular Partners AG's share price for today is CHF3.24.
Molecular Partners AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-1.570.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:MOLN vs VRTX, REGN, RVMD: EV-to-OCF Comparison
For the Biotechnology subindustry, Molecular Partners AG's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Molecular Partners AG EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Molecular Partners AG's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Molecular Partners AG's EV-to-OCF falls into.
Molecular Partners AG's current Enterprise Value is CHF46.11 Mil.
Molecular Partners AG's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-48.42 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Molecular Partners AG (XSWX:MOLN) has a EV-to-OCF of -0.95 as of Aug. 09, 2026. According to the industry distribution chart, Molecular Partners AG ranks #903 out of 1407 companies in the Biotechnology industry, placing it in the top 64.2%.
Is Molecular Partners AG's EV-to-OCF too high?
Molecular Partners AG's current EV-to-OCF is -0.95. Based on the distribution chart, Molecular Partners AG ranks #903 out of 1407 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Molecular Partners AG has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Molecular Partners AG's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Molecular Partners AG ranks #903 out of 1407 companies for EV-to-OCF. This places Molecular Partners AG in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Molecular Partners AG's current EV-to-OCF is -0.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Molecular Partners AG stock overvalued right now?
Molecular Partners AG (XSWX:MOLN) has a current EV-to-OCF of -0.95. The current EV-to-OCF is -0.95. Molecular Partners AG's overall GF Score™ is 29/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Molecular Partners AG (XSWX:MOLN), the current EV-to-OCF is -0.95 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
29GF Score
Get the complete analysis for XSWX:MOLN
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:MOLN has been successfully added to your 
